AstraZeneca (AZN) Announces EU Approval of Imfinzi for Early Gastric/Gastroesophageal Cancers

AstraZeneca PLC (NYSE:AZN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds.

On March 16, 2026, AstraZeneca PLC (NYSE:AZN) announced that Imfinzi, in combination with FLOT chemotherapy, has been approved in the European Union for treating adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. The company said the regimen includes treatment before and after surgery, followed by Imfinzi monotherapy, with the approval based on results from the Phase III MATTERHORN trial published in The New England Journal of Medicine.

On March 10, 2026, Guggenheim raised its price target on AstraZeneca PLC (NYSE:AZN) to 16,000 GBp from 15,500 GBp previously and maintained a Buy rating after updating its model following FY25 results and recent investor discussions.

AstraZeneca (AZN) Announces EU Approval of Imfinzi for Early Gastric/Gastroesophageal Cancers

On March 9, 2026, AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo announced that the supplemental biologics license application for Enhertu was accepted and granted priority review in the U.S. for patients with HER2-positive breast cancer with residual disease after prior treatment.

Earlier in March, Morgan Stanley raised its price target on AstraZeneca to $219 from $109 and maintained an Overweight rating, citing updated risk/reward and pointing to sector-leading earnings growth supported by a stronger pipeline outlook, with more favorable positioning expected into the second half of 2026.

AstraZeneca PLC (NYSE:AZN) develops and commercializes prescription medicines across multiple therapeutic areas, including oncology.

While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.